Heterologous Expression and Purification of the Antimicrobial Peptide Buforin II

1. Mahlapuu M, Håkansson J, Ringstad L, Björn C. Antimicrobial Peptides: An Emerging Category of Therapeutic Agents. Front Cell Infect Microbiol. 2016;6:194.10.3389/fcimb.2016.00194Search in Google Scholar

2. Zhang L-J, Gallo RL. Antimicrobial peptides. Curr Biol. 2016 Jan 11;26(1):R14-9.10.1016/j.cub.2015.11.017Search in Google Scholar

3. Bahar A, Ren D, Bahar AA, Ren D. Antimicrobial Peptides. Pharmaceuticals. 2013 Nov 28;6(12):1543–75.10.3390/ph6121543Search in Google Scholar

4. Fjell CD, Hiss JA, Hancock REW, Schneider G. Designing antimicrobial peptides: Form follows function. Nat Rev Drug Discov. 2012;11:37–51.10.1038/nrd3591Search in Google Scholar

5. Lakshmaiah Narayana J, Chen JY. Antimicrobial peptides: Possible anti-infective agents. Peptides. 2015;72:88–94.10.1016/j.peptides.2015.05.012Search in Google Scholar

6. Li Y, Xiang Q, Zhang Q, Huang Y, Su Z. Overview on the recent study of antimicrobial peptides: origins, functions, relative mechanisms and application. Peptides. 2012;37:207–15.10.1016/j.peptides.2012.07.001Search in Google Scholar

7. Hancock REW, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat Biotechnol. 2006;24(12):1551–7.10.1038/nbt1267Search in Google Scholar

8. Kosikowska P, Lesner A. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015). Expert Opin Ther Pat. 2016;26(6):689–702.10.1080/13543776.2016.1176149Search in Google Scholar

9. Fox JL. Antimicrobial peptides stage a comeback. Nat Biotechnol. 2013;31(5):379–82.10.1038/nbt.2572Search in Google Scholar

10. Park CB, Kim MS, Kim SC. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem Biophys Res Commun. 1996;218:408–13.10.1006/bbrc.1996.0071Search in Google Scholar

11. Park CB, Kim HS, Kim SC. Mechanism of action of the antimicrobial peptide buforin II: Buforin II kills microorganisms by penetrating the cell membrane and inhibiting cellular functions. Biochem Biophys Res Commun. 1998;244:253–7.10.1006/bbrc.1998.8159Search in Google Scholar

12. Uyterhoeven ET, Butler CH, Ko D, Elmore DE. Investigating the nucleic acid interactions and antimicrobial mechanism of buforin II. FEBS Lett. 2008;582:1715–8.10.1016/j.febslet.2008.04.036Search in Google Scholar

13. Lee HS, Park CB, Kim JM, Jang SA, Park IY, Kim MS, et al. Mechanism of anticancer activity of buforin IIb, a histone H2A-derived peptide. Cancer Lett. 2008;271:47–55.10.1016/j.canlet.2008.05.041Search in Google Scholar

14. Marqus S, Pirogova E, Piva TJ. Evaluation of the use of therapeutic peptides for cancer treatment. J Biomed Sci. 2017;24:21.10.1186/s12929-017-0328-xSearch in Google Scholar

15. Salamon P, Miklóssy I, Albert B, Korodi M, Nagy K, Bakos I, et al. Heterologous Expression and Purification of Recombinant Proapoptotic Human Protein Smac/Diablo with EGFP as Fusion Partner. Stud Univ Babeș-Bolyai Chem. 2017 Jun;62(2):333–45.10.24193/subbchem.2017.2.26Search in Google Scholar

16. Boda FA, Salamon P, Orbán C, Berta L, Curticăpean A, Gâz Șerban A, et al. Heterologous expression and purification of recombinant crotoxin B, the phospholipase A2 subunit of crotoxin. Stud Univ Babes-Bolyai Chem. 2018;10.24193/subbchem.2018.1.01Search in Google Scholar

17. Wang Q, Zhu F, Xin Y, Liu J, Luo L, Yin Z. Expression and purification of antimicrobial peptide buforin IIb in Escherichia coli. Biotechnol Lett. 2011;33:2121–6.10.1007/s10529-011-0687-4Search in Google Scholar